Targeted radionuclide therapy for neuroendocrine tumours: principles and application

Area of Science:

• Oncology
• Nuclear Medicine
• Endocrinology

Background:

• Neuroendocrine tumors (NETs) are rare neoplasms with variable behavior, often diagnosed at a metastatic stage and incurable by surgery.
• Slow growth and initial asymptomatic presentation contribute to late-stage diagnosis.

Purpose of the Study:

• To review the principles of targeted radionuclide therapy for NETs.
• To summarize current clinical outcomes and discuss future research directions for this therapeutic strategy.

Main Methods:

• Review of existing literature and clinical data on targeted radionuclide therapy in neuroendocrine tumors.
• Analysis of evidence from randomized controlled trials, acknowledging limitations due to disease rarity.

Main Results:

• Targeted radionuclide therapy is an emerging strategy for cytoreduction in NETs.
• This therapy aims to stabilize tumor growth and inhibit hormone production.
• Current data, though limited by trial size, appear promising for managing NETs.

Conclusions:

• Targeted radionuclide therapy presents a viable and promising approach for managing advanced or metastatic neuroendocrine tumors.
• Despite challenges in conducting large-scale trials for rare diseases, the evidence supports its role in cytoreduction and symptom management.
• Future research should focus on refining techniques and expanding evidence for this innovative treatment modality.